Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Buy Rating at Needham & Company LLC

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report)'s stock had its "buy" rating reissued by Needham & Company LLC in a report released on Friday,Benzinga reports. They presently have a $320.00 price objective on the biopharmaceutical company's stock. Needham & Company LLC's price objective suggests a potential upside of 13.90% from the company's current price.

A number of other research firms have also weighed in on ALNY. HC Wainwright raised their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a "buy" rating in a research note on Monday, February 24th. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday. Bank of America raised their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research report on Friday. Sanford C. Bernstein decreased their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. Finally, Canaccord Genuity Group boosted their price objective on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $312.30.

Remove Ads

Alnylam Pharmaceuticals Trading Down 3.4 %

ALNY traded down $9.74 during trading on Friday, reaching $280.96. 1,065,379 shares of the stock traded hands, compared to its average volume of 806,039. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The stock's 50-day moving average is $258.62 and its 200 day moving average is $260.26. The stock has a market capitalization of $36.37 billion, a PE ratio of -129.47 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the transaction, the chief executive officer now directly owns 81,526 shares of the company's stock, valued at $20,802,989.42. The trade was a 1.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of the company's stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is currently owned by insiders.

Institutional Trading of Alnylam Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its holdings in Alnylam Pharmaceuticals by 2.6% in the 4th quarter. California State Teachers Retirement System now owns 196,362 shares of the biopharmaceutical company's stock worth $46,206,000 after purchasing an additional 5,037 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Alnylam Pharmaceuticals by 94.7% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 12,566 shares of the biopharmaceutical company's stock valued at $2,957,000 after buying an additional 6,112 shares during the period. Lansforsakringar Fondforvaltning AB publ purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $10,011,000. Bannerman Wealth Management Group LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth about $327,000. Finally, Siemens Fonds Invest GmbH lifted its holdings in Alnylam Pharmaceuticals by 137.7% in the fourth quarter. Siemens Fonds Invest GmbH now owns 3,245 shares of the biopharmaceutical company's stock worth $764,000 after buying an additional 1,880 shares during the period. Institutional investors own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.